KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Non-Current Deferred Tax Liability (2021 - 2022)

Pacific Biosciences Of California has reported Non-Current Deferred Tax Liability over the past 2 years, most recently at $835000.0 for Q4 2022.

  • Quarterly results put Non-Current Deferred Tax Liability at $835000.0 for Q4 2022, changed 0.36% from a year ago — trailing twelve months through Dec 2022 was $835000.0 (changed 0.36% YoY), and the annual figure for FY2022 was $835000.0, changed 0.36%.
  • Non-Current Deferred Tax Liability for Q4 2022 was $835000.0 at Pacific Biosciences Of California, roughly flat from $838000.0 in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for PACB hit a ceiling of $838000.0 in Q4 2021 and a floor of $835000.0 in Q4 2022.